Welcome to our dedicated page for Immunitybio SEC filings (Ticker: IBRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ImmunityBio, Inc. (NASDAQ: IBRX) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including annual reports, quarterly reports, and current reports on Form 8‑K. As a commercial-stage biotechnology issuer focused on IL‑15–based immunotherapies and cell therapies, ImmunityBio uses these filings to report financial performance, capital structure changes, governance matters, and material agreements related to its ANKTIVA‑centered portfolio.
Annual reports (Form 10‑K) and quarterly reports (Form 10‑Q) detail product revenue from ANKTIVA, research and development spending on programs such as QUILT‑3.032 in non‑muscle invasive bladder cancer and QUILT‑2.023/3.055 in non‑small cell lung cancer, and broader risk factors associated with developing and commercializing biologic therapies. These filings also summarize segment information, which the company describes as including the United States and Europe, and discuss liquidity, debt obligations, and equity plans.
Current reports (Form 8‑K) capture specific material events. Recent 8‑Ks disclose an at‑the‑market offering program amendment authorizing additional common stock sales under a shelf registration statement, a registered direct offering of common shares and warrants, adoption of the 2025 Equity Incentive Plan, and the appointment of independent directors. Other 8‑Ks reference earnings press releases that report net product revenue growth for ANKTIVA and changes in cash, cash equivalents, and marketable securities.
Investors interested in capital markets activity can review filings describing increases in authorized common stock, revenue interest liabilities, and equity incentive structures. Governance‑focused readers can examine disclosures on board composition, director compensation policies, and the preliminary approval of a settlement of stockholder derivative actions that includes corporate governance reforms.
Stock Titan enhances these filings with AI‑powered summaries that explain key points in accessible language. Instead of parsing lengthy 10‑K or 10‑Q documents line by line, users can see concise overviews of ImmunityBio’s revenue trends, R&D priorities, financing arrangements, and risk disclosures, then drill down into the original SEC documents when more detail is needed.
For those tracking IBRX insider and executive activity, forms such as Form 4 and proxy‑related materials (when available) provide insight into equity awards, option grants, and ownership changes, complementing the broader financial and operational picture presented in periodic reports.
A holder of ImmunityBio (symbol IBRX) has filed a Rule 144 notice to sell 50,000 shares of common stock. The shares are to be sold through Morgan Stanley Smith Barney LLC on the NASDAQ, with an aggregate market value of $197,500 based on the figures in the notice. The filing lists 984,965,179 shares outstanding as a baseline figure for the issuer’s common stock.
The securities to be sold were acquired on 01/16/2026 by an exercise of stock options from the issuer, paid in cash, with the same date shown for payment. By signing the notice, the seller represents that they do not know of any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed, consistent with the representations referenced in Rule 144 and any Rule 10b5-1 trading plan disclosures.
ImmunityBio, Inc. filed a current report to disclose that it issued a press release with certain preliminary, unaudited financial results for the fiscal quarter and full year ended December 31, 2025, along with other company updates. These figures are based on information available as of the press release date and are not a comprehensive statement of its operating results or financial position.
The company notes that final results to be reported in its Annual Report on Form 10-K for the year ended December 31, 2025 will follow normal financial closing procedures and may differ materially from the preliminary estimates. The press release is furnished, not filed, meaning it is not subject to certain Exchange Act liabilities and is not automatically incorporated into other securities filings unless specifically referenced.
ImmunityBio, Inc. reported that the Saudi Food and Drug Authority has granted accelerated approval for its immunotherapy ANKTIVA in two cancer indications. ANKTIVA was approved for use with immune checkpoint inhibitors to treat adult patients with metastatic non-small cell lung cancer whose disease has progressed after standard-of-care therapy. It was also approved in combination with BCG for adult patients with BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ, with or without papillary disease. The company disclosed these updates through press releases that are furnished as exhibits.
ImmunityBio, Inc. amended its existing Open Market Sale Agreement with Jefferies to expand its at-the-market stock offering program. The amendment authorizes the issuance of up to an additional $459,972,480 of common shares, which were registered under a new prospectus supplement dated December 23, 2025 and issued under the company’s effective Form S-3ASR shelf registration.
The company also highlighted that a previously approved Certificate of Amendment to its charter became effective on November 10, 2025, increasing authorized common shares from 1,350,000,000 to 1,650,000,000. Legal opinions and the amendment documents are filed as exhibits, supporting the validity of the newly registered shares and the updated ATM program.
ImmunityBio, Inc. is registering and may sell up to $459,972,480 of its common stock from time to time through Jefferies LLC under an at-the-market offering program. Jefferies will act as sales agent on commercially reasonable efforts terms and receive up to 3.0% of the gross proceeds as commission.
The company plans to use net proceeds, together with other funds, to continue commercializing its FDA- and MHRA‑approved bladder cancer therapy ANKTIVA, fund clinical trials and broader research and development, and support working capital and general corporate purposes, with potential use for licensing or acquisitions. Because shares will be sold into the market at prevailing prices, investors face risks of share price volatility, uncertain total proceeds, and dilution, including immediate and substantial dilution relative to net tangible book value illustrated in the filing.
ImmunityBio, Inc. director reported receiving a new stock option grant for 146,020 shares of common stock at an exercise price of $2.36 per share, expiring on December 12, 2035.
The award was granted under the 2025 Equity Incentive Plan and vests in three annual installments, with 48,673 options vesting on December 12, 2026, 48,673 on December 12, 2027 and 48,674 on December 12, 2028, as long as the director continues as a service provider.
Any unvested options will fully vest immediately before a Change in Control, as defined in the 2025 Equity Incentive Plan, if the director remains a service provider through that date.
ImmunityBio, Inc. disclosed that one of its directors filed an initial insider ownership statement effective 12/12/2025, reporting no beneficial ownership of ImmunityBio securities.
The filing shows the director does not hold any shares or derivative securities of the company, was filed by a single reporting person, and was signed by /s/ Philip LoScalzo as attorney-in-fact.
ImmunityBio, Inc. appointed Bruce Wendel to its board of directors, effective December 12, 2025, with his term running until the 2026 annual meeting of stockholders. The board determined that he qualifies as an independent director under Nasdaq and SEC rules.
Wendel brings extensive pharmaceutical and biotech experience, including senior roles at ProMetic Biosciences, Hepalink USA, Scientific Protein Laboratories, Abraxis BioScience, Bristol-Myers Squibb, IVAX, and American Pharmaceutical Partners, as well as prior public company board service at GT BioPharma and Verastem.
As a non-employee director, he will receive $50,000 in annual cash compensation and an initial stock option grant under ImmunityBio’s 2025 Equity Incentive Plan with a Black-Scholes value of $300,000, vesting over three years and fully vesting immediately before a Change in Control, along with reimbursement of reasonable travel expenses.
ImmunityBio (IBRX) filed its Q3 2025 report showing rapid revenue ramp but continued losses and liquidity pressure. Total revenue reached $32.1 million for the quarter, up from $6.1 million a year ago, driven by U.S. commercialization of ANKTIVA. For the nine months, revenue was $75.0 million versus $7.2 million in 2024.
The company reported a Q3 net loss of $67.3 million and a loss from operations of $55.6 million. Year-to-date operating cash outflows were $234.6 million. Cash and cash equivalents were $60.2 million and marketable securities were $197.6 million as of September 30, 2025. Accounts receivable increased to $32.0 million, reflecting growing product sales.
Total liabilities were $1.04 billion, including a related-party convertible note at fair value of $500.8 million, a revenue interest liability of $316.1 million, and warrant liabilities of $115.2 million. The company raised $346.8 million net through equity offerings year-to-date, including “at-the-market” sales and other equity issuances. Shares outstanding were 984,965,179 as of October 30, 2025.
Management disclosed substantial doubt about continuing as a going concern without additional funding, noting reliance on existing cash, product sales, future equity offerings, and potential affiliated loans. In July 2025, ANKTIVA received UK marketing authorization, the first approval outside the U.S.
ImmunityBio, Inc. furnished a press release announcing its financial results for the third quarter and nine months ended September 30, 2025, and its financial position as of September 30, 2025.
The press release, dated November 4, 2025, is included as Exhibit 99.1 to this Form 8-K. The information under Item 2.02 (including Exhibit 99.1) is being furnished, not filed, under the Exchange Act.
FAQ
What is the current stock price of Immunitybio (IBRX)?
What is the market cap of Immunitybio (IBRX)?
